Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MAIA Biotechnology, Inc.
< Previous
1
2
Next >
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
July 23, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
June 07, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
June 06, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
June 04, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Present at the BIO International Convention 2024
May 17, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
May 16, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
April 30, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
April 29, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces $1.00 Million Private Placement
April 23, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
April 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
March 28, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
March 26, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces $1.33 Million Private Placement
March 26, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
March 22, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
March 21, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
March 07, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
March 06, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
March 06, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
March 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
February 07, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
January 17, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
January 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
December 19, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
November 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces $4 Million Registered Direct Offering
November 15, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
November 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
November 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
October 30, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
October 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.